Mov Disord Vol 34, Suppl 2 Archives - Page 147 of 217 - MDS Abstracts

2019 International Congress
Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease
F. Artaud, PC. Lee, M. Vidailhet, JC. Corvol, A. Elbaz (Saint-Aubin, France)
Objective: To describe the longitudinal relation between dopaminergic agonists (DA) use and change of BMI in a longitudinal cohort of PD patients followed annually up…
2019 International Congress
Inflammatory Conditions in Parkinson’s Disease
B. Krishnamachari, S. Shermon, M. Goldfinger, A. Leder, B. Harper, J. Donoghue (Old Westbury, NY, USA)
Objective: The goal was to conduct a case-control study to assess associations between Parkinson disease (PD) and inflammatory conditions including allergies, asthma, eczema, atopic conditions,…
2019 International Congress
Patterns of Lewy body dementia diagnosis and treatment in Florida
M. Armstrong, R. Eisinger, C. Garvan, B. Patel (Gainesville, FL, USA)
Objective: To characterize the demographic and treatment characteristics for the Lewy body dementia (LBD) population in Florida using a statewide clinical data research network. Background:…
2019 International Congress
Development of a Predictive Model for Progressive Supranuclear Palsy Using Real World Data
E. Viscidi, Y. Zabar, T. Dam, M. Juneja, J. Kupferman, V. Kupelian, S. Eaton, I. Litvan, G. Hoglinger (Cambridge, MA, USA)
Objective: To examine diagnoses and symptoms in progressive supranuclear palsy (PSP) patients in the 5 years before PSP diagnosis and to develop a model to…
2019 International Congress
Structural changes in non-manifesting GBA mutation carriers and GBA mutation carriers with Parkinson’s disease
T. Yousaf, M. Kershaw, V. Suarez Contreras, P. Vickers, G. Pagano, M. Politis (London, United Kingdom)
Objective: We aimed to investigate whether GBA mutations are associated with structural abnormalities in a cohort of GBA mutation carriers with and without manifested PD.…
2019 International Congress
Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats
CB. Cho, JH. Sung (Suwon, Republic of Korea)
Objective: Globus pallidus interna (GPi) is recognized as an effective treatment for advanced Parkinson’s disease. However, the neurochemical basis of its effects remains unknown. The…
2019 International Congress
Karl Marx, Rosa Luxemburg, and Deep Brain Stimulation: is there a connection?
M. Hariz, P. Krack, A. Lees (Umea, Sweden)
Objective: To investigate possible reasons behind some practices of deep brain stimulation (DBS) hardware providers. Background: The global success of DBS in movement disorders has…
2019 International Congress
Directional Deep Brain Stimulation Lead Implantation: A Single Center Experience
R. Kochanski, A. Borghei, G. Pal, L. Verhagen Metman, F. Lynn, J. Karl, S. Sani (Chicago, IL, USA)
Objective: The authors’ experience with implantation of the first 100 patients implanted with Abbott St. Jude Medical Infinity™ DBS lead system. Background: The introduction of…
2019 International Congress
The relationship between brain edema after deep brain stimulation surgery and the function of motor and cognition
Y. Nishiguchi, K. Matsuura, S. Sakano, Y. Hirata, A. Mizutani, N. Katoh, A. Ito, K. Tachibana, H. Ishikawa, K. Miyashita, T. Utsunomiya, H. Kajikawa, T. Yamanaka, H. Nishikawa, T. Araki, H. Tomimoto (Tsu-Shi, Mie, Japan)
Objective: To investigate the relationship between brain edema after deep brain stimulation (DBS) surgery and the function of motor and cognitive function. Background: DBS surgery…
2019 International Congress
Use of directional stimulation to localize and troubleshoot STN-related contralateral gaze deviation: a case report
C. Stahl, C. Cho, A. Mogilner, M. Pourfar (New York, NY, USA)
Objective: To report a case in which STN stimulation-induced gaze deviation was mapped and managed using directional lead programming. Background: Deep Brain Stimulation (DBS) of…